TrialThe Journal of infectious diseases2022

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Arabella S V Stuart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.